VIDEO: Win-win with denosumab as adjuvant therapy for post-menopausal breast cancer

SAN ANTONIO – Adding denosumab to adjuvant aromatase inhibitor therapy, not only reduced risk of fracture, but also improved disease-free survival for postmenopausal patients with early-stage, hormone receptor–positive breast cancer, according to results presented at the San Antonio Breast Cancer Symposium.

In an interview, Dr. Michael Gnant, professor of surgery at the Medical University of Vienna, discusses the phase III ABCSG-18 clinical trial, and why he will now be prescribing denosumab to HR-positive breast cancer patients who are receiving adjuvant aromatase inhibitor therapy, regardless of their bone health status.

[email protected]

SAN ANTONIO – Adding denosumab to adjuvant aromatase inhibitor therapy, not only reduced risk of fracture, but also improved disease-free survival for postmenopausal patients with early-stage, hormone receptor–positive breast cancer, according to results presented at the San Antonio Breast Cancer Symposium.

In an interview, Dr. Michael Gnant, professor of surgery at the Medical University of Vienna, discusses the phase III ABCSG-18 clinical trial, and why he will now be prescribing denosumab to HR-positive breast cancer patients who are receiving adjuvant aromatase inhibitor therapy, regardless of their bone health status.

[email protected]

SAN ANTONIO – Adding denosumab to adjuvant aromatase inhibitor therapy, not only reduced risk of fracture, but also improved disease-free survival for postmenopausal patients with early-stage, hormone receptor–positive breast cancer, according to results presented at the San Antonio Breast Cancer Symposium.

In an interview, Dr. Michael Gnant, professor of surgery at the Medical University of Vienna, discusses the phase III ABCSG-18 clinical trial, and why he will now be prescribing denosumab to HR-positive breast cancer patients who are receiving adjuvant aromatase inhibitor therapy, regardless of their bone health status.

[email protected]